Many important drugs needed in the fight against chronic diseases have been taken off the market or become prohibitively expensive, because the drugs were not used frequently enough or were not profitable enough. The importance of some drugs is underappreciated, such as mebendazole, metronidazole, pyrimethamine (Daraprim), and imiquimod (Aldera/TLR-7 agonist). Enteric (intestinal) pathogens and parasites must be able to survive in a low oxygen environment. “Azole” drugs are effective against many enteric pathogens and some chlamydia pathogens. Daraprim (in combination with an antibiotic) is effective against toxoplasmosis, but costs as much as $75,000 per month, requires six weeks of treatment, and the significance of toxoplasmosis in chronic disease and mental health is seldom recognized. Imiquimod is a crème applied to the skin, which attracts immune cells to the location where applied; and has been shown effective in treating warts, cancer, lymphoma, and metastatic breast cancer. Later generations of imiquimod (TLR-8 and TLR-9) have recently been used successfully in clinical trials for targeted cancer therapy. Medicine needs to recognize the importance of these classes of drugs, use them against infectious pathogens causing chronic disease, and take steps to reduce the price of these drugs.